TIR

Meller Optics Introduces Sight Glass Viewports that Provide Full 360 Degree Viewing

Retrieved on: 
Tuesday, January 10, 2023
Diamond, Hardness, SWIR, Glass, TIR, SPIE, UV, Gemstone, Telescopic sight

PROVIDENCE, R.I., Jan. 10, 2023 /PRNewswire-PRWeb/ -- Meller Optics, Inc. has introduced new custom optical grade sight glass viewports made from sapphire for optimum hardness and durability or from glass for less hostile environments.

Key Points: 
  • New, custom optical grade sight glass viewports made from sapphire for optimum hardness and durability or from glass for less hostile environments have been introduced by Meller Optics, Inc.
    PROVIDENCE, R.I., Jan. 10, 2023 /PRNewswire-PRWeb/ -- Meller Optics, Inc. has introduced new custom optical grade sight glass viewports made from sapphire for optimum hardness and durability or from glass for less hostile environments.
  • Meller Sight Glass Viewports made from sapphire exhibit Mohs 9 hardness which is second only to diamond, making them ideal for applications in hostile environments, and feature 0.001" TIR thickness.
  • sizes and all of these sight glass viewports can incorporate steps, tapers, beveled edges for sealing, and polished edges.
  • Meller Sight Glass Viewports made from sapphire or glass are priced according to material, configuration, and quantity.

SAE TIR J2954/2 Paves the Way for Heavy-Duty EV Charging Without a Plug & Static and Dynamic Wireless Power Transfer

Retrieved on: 
Monday, December 19, 2022
Transfer, Collegiate, Learning, EV, SAE International, Power, National Technical Information Service, ZEV, AC, Guideline, HD, Utah State University, Certification, Wireless power transfer, EVS, World Wireless System, WAVE, TIR, Memorandum of understanding, WPT, MIT EAD Airframe Version 2, SAE J2954, Alignment, UL, Volunteering, SAE, Mobile phone, Electric motor

WARRENDALE, Pa., Dec. 19, 2022 /PRNewswire-PRWeb/ -- SAE International announces the publication of the first Technical Information Report (TIR) that specifies, in a single document, both electric vehicle (EV) and ground-system requirements for heavy-duty (HD) wireless charging of EVs. SAE TIR J2954/2 Wireless Power Transfer & Alignment for Heavy-Duty Applications paves the way for charging HD vehicles without the need for plugging in – widely considered to be a key enabler for accelerating the adoption of EVs and autonomous vehicles. This new guideline builds off the success of the first light-duty SAE J2954 standard published in 2020. The SAE TIR J2954/2 exponentially increases the power level of Wireless Power Transfer (WPT) for heavy-duty vehicles.

Key Points: 
  • The SAE TIR J2954/2 exponentially increases the power level of Wireless Power Transfer (WPT) for heavy-duty vehicles.
  • "Charging a heavy-duty EV should be as simple as parking in the right spot – the wireless charging SAE TIR J2954/2 Guideline makes it possible to do that automatically," stated Jesse Schneider, chair of the SAE Wireless Power Transfer Task Force (ZEV Station).
  • "The SAE TIR J2954/2 is a game-changer guideline enabling ultra-fast wireless charging to 500kW, for both trucks and buses.
  • SAE J2954 recently published an updated Version 2 of its SAE J2954 light-duty standard for wireless power transfer for electric vehicles.

New International Consensus on CGM Clinical Trial Metrics Aims to Spur Diabetes Treatment Advances

Retrieved on: 
Tuesday, December 6, 2022
Online, American Diabetes Association, Ljubljana University Medical Centre, International Conference on Population and Development, JDRF, Food, European Association for the Study of Diabetes, Human, Endocrinology, Conference, International Society for Pediatric and Adolescent Diabetes, DCCT, International Society, ATTD, Israel Advanced Technology Industries, Patient, Science, CGM, Collection, CGMS-A, Research, Adolescence, Treatment, Disease, Blood, Obesity, Quality of life, US Food Sovereignty Alliance, European Medicines Agency, Paper, News, The Lancet, TIR, SAN, Pharmaceutical industry, Cryptocurrency, Diabetes

The groundbreaking consensus statement, endorsed by numerous leading US and international diabetes organizations, including the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care and Education Specialists, DiabetesIndia, European Association for the Study of Diabetes, International Society for Pediatric and Adolescent Diabetes, Japan Diabetes Society, and JDRF, was published in The Lancet Diabetes & Endocrinology on December 6, 2022.

Key Points: 
  • The groundbreaking consensus statement, endorsed by numerous leading US and international diabetes organizations, including the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care and Education Specialists, DiabetesIndia, European Association for the Study of Diabetes, International Society for Pediatric and Adolescent Diabetes, Japan Diabetes Society, and JDRF, was published in The Lancet Diabetes & Endocrinology on December 6, 2022.
  • The article, "Continuous glucose monitoring and metrics for clinical trials: an international consensus statement," is available here .
  • "Standardizing the use of CGM data in clinical trials of diabetes therapies will help ensure that the next generation of treatments are focused on increasing patients' TIR and, therefore, quality of life."
  • As such, earlier this year, the diaTribe Foundation, ATTD, and the Time in Range Coalition convened a group of international experts to discuss and reach consensus on the role of CGMs and CGM-derived metrics in clinical trials for diabetes treatment.

New International Consensus on CGM Clinical Trial Metrics Aims to Spur Diabetes Treatment Advances

Retrieved on: 
Tuesday, December 6, 2022
Online, American Diabetes Association, Ljubljana University Medical Centre, International Conference on Population and Development, JDRF, Food, European Association for the Study of Diabetes, Human, Endocrinology, Conference, International Society for Pediatric and Adolescent Diabetes, DCCT, International Society, ATTD, Israel Advanced Technology Industries, Patient, Science, CGM, Collection, CGMS-A, Research, Adolescence, Treatment, Disease, Blood, Obesity, Quality of life, US Food Sovereignty Alliance, European Medicines Agency, Paper, News, Multimedia, The Lancet, TIR, SAN, Pharmaceutical industry, Cryptocurrency, Diabetes

The groundbreaking consensus statement, endorsed by numerous leading US and international diabetes organizations, including the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care and Education Specialists, DiabetesIndia, European Association for the Study of Diabetes, International Society for Pediatric and Adolescent Diabetes, Japan Diabetes Society, and JDRF, was published in The Lancet Diabetes & Endocrinology on December 6, 2022.

Key Points: 
  • The groundbreaking consensus statement, endorsed by numerous leading US and international diabetes organizations, including the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care and Education Specialists, DiabetesIndia, European Association for the Study of Diabetes, International Society for Pediatric and Adolescent Diabetes, Japan Diabetes Society, and JDRF, was published in The Lancet Diabetes & Endocrinology on December 6, 2022.
  • The article, "Continuous glucose monitoring and metrics for clinical trials: an international consensus statement," is available here .
  • "Standardizing the use of CGM data in clinical trials of diabetes therapies will help ensure that the next generation of treatments are focused on increasing patients' TIR and, therefore, quality of life."
  • As such, earlier this year, the diaTribe Foundation, ATTD, and the Time in Range Coalition convened a group of international experts to discuss and reach consensus on the role of CGMs and CGM-derived metrics in clinical trials for diabetes treatment.

Continuous Glucose Monitoring (CGM) Market to Grow by 13% Annually Through 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 5, 2022
Health, Diabetes, Adoption, Disease, Diabetes, Risk, Government, Hospital, Therapy, TIR, Glucose oxidase, Population, Platinum, CAGR, Patient, Virus, Science, Technology, Partnership, Glucose meter, CGM, Continuous glucose monitor, Association, Korean Association of Retired Persons, Death, COVID-19, USD, Pharmaceutical industry, Medical imaging, Medical device, Growth, Spectrum

The "Continuous Glucose Monitoring (CGM) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Continuous Glucose Monitoring (CGM) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Continuous Glucose Monitoring (CGM) Market is expected to register a CAGR greater than 13% over the forecast period, 2022-2027.
  • Governments around the world developed programs to educate diabetes patients and health care providers about the usage of continuous glucose monitoring devices.
  • Continuous glucose monitoring has become a popular alternative to the portable finger-prick glucometers available in the market for the convenience of diabetic patients.

Cecelia Health Celebrates 2022 Donnelly Scholarship Recipients

Retrieved on: 
Wednesday, September 21, 2022
Athlete, Essay, Fouad Abiad, TIR, Blog, Tennis, NEW, Life, Diabetes, Program, Clinical trial, Exercise, Student, Solution, US, Health, Medicine

NEW YORK, Sept. 21, 2022 /PRNewswire-PRWeb/ -- Cecelia Health today shared their participation in the 2022 Novo Nordisk Donnelly Scholarship. The two national recipients, Anne Marie Hiser (Acworth, Ga.) and Bogdan Vizoli (Woodbury, Minn.), were awarded scholarships of $10,000 each last month and celebrated at a reception during the first week of the US Open where they visited with sports icon Billie Jean King as well as leaders from Cecelia Health and other scholarship sponsors.

Key Points: 
  • Cecelia Health continues to support Novo Nordisk Donnelly Scholarship program, providing virtual, human-led disease education & support to young tennis athletes living with diabetes.
  • NEW YORK, Sept. 21, 2022 /PRNewswire-PRWeb/ -- Cecelia Health today shared their participation in the 2022 Novo Nordisk Donnelly Scholarship.
  • "Cecelia Health is honored to support the Novo Nordisk Donnelly Scholarship program," said Mark Clermont, chief executive officer at Cecelia Health.
  • Cecelia Health delivers virtual care designed with a human element to improve health outcomes of people living with chronic conditions.

12-month real-world achievements for Diabeloop's AID

Retrieved on: 
Wednesday, September 21, 2022
TIR, Population, CMO, Patient, Quality of life, TBR, Hypoglycemia, GLOBE, Medical device

While Time in Range (70-180 mg/dL) still shows constant improvement, time spent in hypoglycemia stays significantly low.

Key Points: 
  • While Time in Range (70-180 mg/dL) still shows constant improvement, time spent in hypoglycemia stays significantly low.
  • In line with previously presented data4, significant improvement in Time in Range is observed here on a much larger population.
  • The cohort gathers 4,162 patients in five countries: Germany, Italy, Spain, The Netherlands and Switzerland.
  • 3 Internal data - May 2021- April 2022, patients equipped with DBLG1 System with Accu-Chek Insight insulin pump
    4 P.Y.

ST98: New Standard in Medical Device Cleaning Spotlights ‘Clean’ for Manufacturers

Retrieved on: 
Thursday, August 25, 2022
AAMI, TIR, Spaulding, Organization, ANSI, GLOBE, FDA, Johnson & Johnson, Intuitive Surgical, Marketing, Medical device

ARLINGTON, Va., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Medical device manufacturers have a new standard for clean.

Key Points: 
  • ARLINGTON, Va., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Medical device manufacturers have a new standard for clean.
  • With the launch of ANSI/AAMI ST98:2022, Cleaning validation of health care productsRequirements for development and validation of a cleaning process for medical devices , manufacturers now have formalized cleaning validation methodology.
  • The document not only advances understanding of and conformance with cleaning best practices but has the potential to have an impact on the design and development of medical devices for years to come.
  • But then it is also revolutionary in the sense that it is really the first document, globally that gives requirements for device manufacturers as far as what they need to do to validate their cleaning [and ensure] their cleaning instructions actually produce a clean device.

Ambrosia Is Launching "Real Time CGM With Activity, Direct To Watch" In 195 Countries

Retrieved on: 
Thursday, August 25, 2022
Android, Android Oreo, CEO, Caregiver, Apple Watch, SAN, A1C, Glucose, TIR, Smartwatch, NightRider, Athlete, CGM, Weight loss, Activity, Diabetes, Patient, Medical device, Mobile phone, Libre, Ambrosia

SAN FRANCISCO , Aug. 25, 2022  /PRNewswire-PRWeb/ -- In a ground-breaking development, Ambrosia is finally set to launch Ambrosia Real-time CGM with Activity in 195 countries. Ambrosia rt-CGM+ is currently the only real-time continuous glucose monitoring system that supports Apple Watch and all Android watches with Wear 2 OS and Android 8 operating systems and can be used without a phone.

Key Points: 
  • The Ambrosia team has already contributed to lowering the cost of real-time CGM by 65% in North America and European countries and by more than 85% in several Asian countries through the use of their innovative technologies.
  • Numerous individuals with diabetes observed a significant improvement in their A1c and Time-in-Range(TIR) post during the past few years, thanks to Ambrosia technology.
  • Those using Ambrosia technology reported a 23% improvement in their A1c and a 47% improvement in TIR when compared to patients using alternative rt-CGMs.
  • As per reports, NightRider BluCon has already helped many people get access to real-time continuous glucose readings in more than 100 countries.

Control-IQ Technology Continues to Demonstrate Positive and Sustained Real-World Benefits Across Diverse Cohorts of People with Diabetes

Retrieved on: 
Monday, June 6, 2022
Diabetes, Health, Medical Devices, Real-World Evidence, Tandem Diabetes Care, Hearing, Diabetes, Behavioural sciences, Safety, ADA, Veni, vidi, vici, CGM, Software, Hydroxycarbamide, Meal, GMI, Insulin pump, Dialysis, American Diabetes Association, TIR, Motivation, Patient, CT, Glycated hemoglobin, Insulin, CLIO, MS, Technology, Medical director, GlySens ICGM, Pregnancy, NASDAQ, ACE, Sleep, Twitter, MD, Insulin aspart, Doctor of Education, Insulin lispro, Poster, Multi, MRI, Person, Tandem, Pharmaceutical industry, Medical device, Adult, White

Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced positive real-world data demonstrating immediate and sustained benefits in a diverse cohort of people using the t:slim X2 insulin pump with Control-IQ technology.

Key Points: 
  • Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced positive real-world data demonstrating immediate and sustained benefits in a diverse cohort of people using the t:slim X2 insulin pump with Control-IQ technology.
  • Psychosocial benefits of Control-IQ technology were experienced by all ethnic cohorts.
  • Multiple daily injection users with relatively high HbA1c values initiating Control-IQ technology showed dramatic and sustained glycemic improvements.
  • Psychosocial Benefits of using the t:slim X2 Insulin Pump with Control-IQ technology: Long-term Outcomes from a Multi-ethnic Adult Cohort with Type 1 Diabetes.